Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20755854 | 1.00 | ANPEP (0.55) | ANPEPLAP3 | |
| SCHEMBL21827375 | 0.79 | ANPEP (0.50) | ANPEPLAP3 | |
| SCHEMBL21190520 | 0.75 | ANPEP (0.60) | ANPEPLAP3 | |
| SCHEMBL819417 | 0.75 | ANPEP (0.60) | ANPEPLAP3 | |
| SCHEMBL15249536 | 0.75 | ANPEP (0.60) | ANPEPLAP3 | |
| SCHEMBL22103066 | 0.75 | ANPEP (0.60) | ANPEPLAP3 | |
| SCHEMBL18255405 | 0.72 | ANPEP (0.57) | ANPEPLAP3 | |
| SCHEMBL10592640 | 0.72 | ANPEP (0.64) | ANPEPLAP3 | |
| SCHEMBL20510145 | 0.72 | ANPEP (0.64) | ANPEPLAP3 | |
| SCHEMBL23266362 | 0.71 | ANPEP (0.55) | ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178620-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12528786-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4665330-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173196-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20230348428-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-116157154-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4178620-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20220213109-A1 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
| WO-2022035763-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022010828-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-3718573-A1 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | University of Washington Through Its Center for Commercialization (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2797635-B1 | CHROMOPHORIC POLYMER DOTS WITH NARROW-BAND EMISSION | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2020-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348428-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | ANPEP 683/4885LAP3 1374/4885 |
| US-20230303534-A1 | PREPARATION METHOD FOR NOVEL RHO-RELATED PROTEIN KINASE INHIBITOR AND INTERMEDIATE IN PREPARATION METHOD | ROCK1, ROCK2, ARHGDIA | ANPEP 2419/4885LAP3 3781/4885 |
| US-12528786-B2 | Plasma kallikrein inhibitors | CFH, KLKB1, SERPINH1 | ANPEP 914/4885LAP3 1447/4885 |
| US-20220213109-A1 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | ANPEP 1874/4885LAP3 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.